Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steato hepatitis

Diabetes Care

Volumn 41, Issue 6, 2018, Pages 1235-1243

  Apostolopoulou, Maria ^a,b,c   Gordillo, Ruth ^d   Koliaki, Chrysi ^b,c   Gancheva, Sofia ^a,b,c   Jelenik, Tomas ^b,c   De Filippo, Elisabetta ^b,c   Herder, Christian ^b,c   Markgraf, Daniel ^b,c   Jankowiak, Frank ^a   Esposito, Irene ^a   Schlensak, Matthias ^e   Scherer, Philipp E ^d   Roden, Michael ^a,b,c  

^a Department of Orthopedic Surgery   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e Epilepsy Center for Children and Adolescents   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE DERIVATIVE; DIHYDROCERAMIDE DERIVATIVE; HEXOSYLCERAMIDE DERIVATIVE; LACTOSYLCERAMIDE DERIVATIVE; LIPID PEROXIDE; SPHINGOLIPID; SPHINGOMYELIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ABDOMINAL SURGERY; ADULT; BARIATRIC SURGERY; CELL RESPIRATION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ACTIVITY; ELECTIVE SURGERY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTOSYLCERAMIDE BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID PEROXIDATION; LIVER METABOLISM; LIVER MITOCHONDRION; MALE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PROSPECTIVE STUDY; TISSUE SPECIFICITY; ANIMAL; BLOOD; CHEMISTRY; DISEASE EXACERBATION; GLUCOSE CLAMP TECHNIQUE; LIVER; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; ANIMALS; DISEASE PROGRESSION; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROSPECTIVE STUDIES; SPHINGOLIPIDS;

EID: 85047500409     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-1318     Document Type: Conference Paper

References (38)

1. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017;14:32-42
2. ChaurasiaB, SummersSA. Ceramidesdlipotoxic inducers of metabolic disorders [published correction appears in Trends Endocrinol Metab 2018;29:66-67].
3. ChaurasiaB, SummersSA. Ceramidesdlipotoxic inducers of metabolic disorders. Trends Endocrinol Metab 2015; 26:538-550
4. Szendroedi J, Yoshimura T, Phielix E, et al. Role ofdiacylglycerol activationofPKCuin lipid-induced muscle insulin resistance in humans. Proc Natl Acad Sci U S A 2014;111:9597-9602
5. Magkos F, Su X, Bradley D, et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 2012;142:1444-1446.e1442
6. Kumashiro N, ErionDM, Zhang D, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 2011; 108:16381-16385
7. Ter Horst KW, Gilijamse PW, Versteeg RI, et al. Hepatic diacylglycerol-associated protein kinase Ce translocation links hepatic steatosis to hepatic insulinresistanceinhumans. CellReports 2017;19: 1997-2004
8. Kotronen A, Seppänen-Laakso T, Westerbacka J, et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 2009;58:203-208
9. Luukkonen PK, Zhou Y, Sädevirta S, et al. Hepatic ceramides dissociate steatosis and insulin resistance in patientswith non-alcoholic fatty liver disease. J Hepatol 2016;64:1167-1175
10. Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. NatRev Endocrinol 2011;8:92-103
11. KoliakiC, Szendroedi J, KaulK, et al. Adaptation of hepaticmitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab 2015;21:739-746
12. Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 2011;14:804-810
13. Gornicka A, Morris-Stiff G, Thapaliya S, Papouchado BG, Berk M, Feldstein AE. Transcriptional profile of genes involved in oxidative stress and antioxidantdefenseina dietarymurinemodel of steatohepatitis. Antioxid Redox Signal 2011;15: 437-445
14. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in nonalcoholic fatty liver diseases. J Hepatol 2002;37: 56-62
15. Novgorodov SA, Riley CL, Yu J, et al. Lactosylceramide contributes to mitochondrial dysfunction in diabetes. J Lipid Res 2016;57:546-562
16. deMelloVD, LankinenM, SchwabU, et al. Link between plasma ceramides, inflammation and insulin resistance: Association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia 2009;52:2612-2615
17. Wigger L, Cruciani-Guglielmacci C, Nicolas A, et al. Plasma dihydroceramides are diabetes susceptibility biomarker candidates inmice and humans. Cell Reports 2017;18:2269-2279
18. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010;16:5286-5296
19. Kleiner DE, Brunt EM, Van Natta M, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring systemfor nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321
20. Apostolopoulou M, Strassburger K, Herder C, et al.; GDS group. Metabolic flexibility and oxidative capacity independently associate with insulin sensitivity in individuals with newly diagnosed type 2 diabetes. Diabetologia 2016;59: 2203-2207
21. Szendroedi J, Chmelik M, Schmid AI, et al. Abnormal hepatic energy homeostasis in type 2 diabetes. Hepatology 2009;50:1079-1086
22. Kuznetsov AV, Kehrer I, Kozlov AV, et al. Mitochondrial ROS production under cellular stress: Comparison of different detectionmethods. Anal Bioanal Chem 2011;400:2383-2390
23. Jelenik T, Séquaris G, Kaul K, et al. Tissuespecific differences in the development of insulin resistance in a mouse model for type 1 diabetes. Diabetes 2014;63:3856-3867
24. Herder C, BongaertsBWC, RathmannW, et al. Association of subclinical inflammation with polyneuropathy in the older population: KORA F4 study. Diabetes Care 2013;36:3663-3670
25. Szendroedi J, Saxena A, Weber KS, et al.; GDS Group. Cohort profile: The German Diabetes Study (GDS). Cardiovasc Diabetol 2016;15:59
26. HollandWL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action inmice. CellMetab 2013;17:790-797
27. Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates thepleiotropic actionsof adiponectin. Nat Med 2011;17:55-63
28. Trevino MB, Mazur-Hart D, Machida Y, et al. Liver perilipin 5 expression worsens hepatosteatosis but not insulinresistanceinhighfat-fedmice. Mol Endocrinol 2015;29:1414-1425
29. UssherJR, Koves TR, CadeteVJ, et al. Inhibition of denovoceramidesynthesis reverses diet-induced insulin resistance and enhanceswhole-body oxygen consumption. Diabetes 2010;59:2453-2464
30. Xia JY, Morley TS, Scherer PE. The adipokine/ ceramide axis: Key aspects of insulin sensitization. Biochimie 2014;96:130-139
31. Warshauer JT, Lopez X, Gordillo R, et al. Effect of pioglitazone on plasma ceramides inadultswith metabolic syndrome. Diabetes Metab Res Rev 2015;31:734-744
32. Patterson RE, Kalavalapalli S, Williams CM, et al. Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity. AmJ Physiol EndocrinolMetab 2016;310: E484-E494
33. García-Ruiz C, Colell A, París R, Fernández-Checa JC. Direct interaction of GD3 ganglioside with mitochondria generates reactiveoxygen species followed by mitochondrial permeability transition, cytochromecrelease, andcaspaseactivation. FASEBJ 2000;14:847-858
34. Gastaldelli A, Harrison S, Belfort-Aguiar R, et al. Pioglitazone in the treatment of NASH: The roleof adiponectin. Aliment Pharmacol Ther 2010; 32:769-775
35. Holland WL, Scherer PE. Structural biology: Receptors grease the metabolic wheels. Nature 2017;544:42-44
36. Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature 2014;510: 58-67
37. Haus JM, Kashyap SR, Kasumov T, et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 2009;58: 337-343
38. Lee BJ, Kim JS, Kim BK, et al. Effects of sphingolipid synthesis inhibition on cholesterol gallstone formation in C57BL/6J mice. J Gastroenterol Hepatol 2010;25:1105-1110